Negative in Ames, human lymphocyte chromosome aberration and rat bone marrow micronucleus assays
“Vibegron was not mutagenic in in vitro microbial reverse mutation (Ames) assays, showed no genotoxic activity in an in vitro human peripheral blood lymphocyte chromosomal aberration assay, and did not increase the frequency of micronucleated polychromatic erythrocytes in an in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Carcinogenicity
2-year mouse and rat: no treatment-related malignancies
“Two year carcinogenicity studies were also conducted in mice and rats, with no treatment-related malignancies observed in either species at adequate exposure margins”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Instead of carcinogenicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Instead of genotoxicity
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
DRG histopathology
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reproductive & developmental
Rat and rabbit EFD: no embryo-fetal toxicity up to 1867-fold (rat) and 285-fold (rabbit) clinical AUC
“No embryo-fetal developmental toxicity was observed in rats at doses up to 300 mg/kg/day (1867-fold the AUC at the clinical dose) or in rabbits at doses up to 100 mg/kg/day (285-fold the AUC at the clinical dose).”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Safety pharmacology
Rhesus monkey: increased heart rate, respiration rate and body temperature
“Cardiac safety pharmacology studies in the rhesus monkey indicated that vibegron significantly increased heart rate, respiration rate and body temperature.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Genotox: Ames
Negative (microbial reverse mutation)
“Vibegron was not mutagenic in in vitro microbial reverse mutation (Ames) assays, showed no genotoxic activity in an in vitro human peripheral blood lymphocyte chromosomal aberration assay, and did not increase the frequency of micronucleated polychromatic erythrocytes in an in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Genotox: in vitro mammalian
Chromosomal aberration in human peripheral blood lymphocytes: negative
“Vibegron was not mutagenic in in vitro microbial reverse mutation (Ames) assays, showed no genotoxic activity in an in vitro human peripheral blood lymphocyte chromosomal aberration assay, and did not increase the frequency of micronucleated polychromatic erythrocytes in an in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Genotox: in vivo
Rat bone marrow micronucleus: negative
“Vibegron was not mutagenic in in vitro microbial reverse mutation (Ames) assays, showed no genotoxic activity in an in vitro human peripheral blood lymphocyte chromosomal aberration assay, and did not increase the frequency of micronucleated polychromatic erythrocytes in an in vivo rat bone marrow micronucleus assay.”
✓ VerifiedFDA pharmacology/toxicology review, p. 12Source ↗
Carcinogenicity model
2-year mouse and rat; no treatment-related malignancies
“Two year carcinogenicity studies were also conducted in mice and rats, with no treatment-related malignancies observed in either species at adequate exposure margins”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
Carcinogenicity timing
2-year mouse and rat studies completed before the marketing application
“Two year carcinogenicity studies were also conducted in mice and rats, with no treatment-related malignancies observed in either species at adequate exposure margins”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
hERG / QT
No significant hERG inhibition at 31 μM (112-fold Cmax at MRHD); 21.4% inhibition at 101 μM (365-fold)
“In CHO-K1 Chinese Hamster Ovary cells, at a concentration of 31 μM (112-fold the MRHD of 75 mg using Cmax)(N=5), MK-4618 had no statistically significant effect on hERG channel tail current, but at the maximum testable concentration of 101 μM (365 fold)(N=4), it inhibited hERG current by 21.4%.”
✓ VerifiedFDA pharmacology/toxicology review, p. 33Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative